The estimated Net Worth of Justin J. File is at least $1.32 Milion dollars as of 20 December 2021. Mr. File owns over 40,594 units of Evofem Biosciences Inc stock worth over $4,329 and over the last 7 years he sold EVFM stock worth over $131,768. In addition, he makes $1,183,010 as Chief Financial Officer at Evofem Biosciences Inc.
Sign up
Mr. File EVFM stock SEC Form 4 insiders trading
Justin has made over 8 trades of the Evofem Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 40,594 units of EVFM stock worth $15,020 on 20 December 2021.
The largest trade he's ever made was buying 40,594 units of Evofem Biosciences Inc stock on 20 December 2021 worth over $15,020. On average, Justin trades about 3,898 units every 29 days since 2018. As of 20 December 2021 he still owns at least 480,982 units of Evofem Biosciences Inc stock.
You can see the complete history of Mr. File stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Justin File biography
Justin J. File serves as Chief Financial Officer of the Company. Mr. File has also served as the Chief Financial Officer of the women’s health nonprofit organization WCG Cares from November 2017 to May 2018. Mr. File has approximately 26 years of diverse accounting and finance experience within a variety of both public and private biotechnology and biopharmaceutical companies. Most recently, Mr. File provided executive financial and accounting oversight services to various biotechnology companies in San Diego, California, assisting in their initial public offering process and helping to establish and improve their accounting and finance operations as publicly-traded entities. Prior to this, Mr. File was Senior Director and Controller of Sequenom, Inc., a diagnostic company that developed and commercialized molecular diagnostics testing services for the women’s health market. During that time, Mr. File served as Treasurer of their diagnostic subsidiary and provided assistance in the raising of over $400 million in combined equity and convertible note offerings. Mr. File also assisted in the commercialization of four diagnostic tests in a two-year period, which included Sequenom’s revolutionary noninvasive prenatal test for Down syndrome. Earlier in his career Mr. File worked for approximately ten years in public accounting, primarily with Arthur Andersen LLP, where he worked with a variety of clients assisting with attestation and periodic reporting requirements, public offerings and acquisitions. Mr. File graduated from Central Washington University with a Bachelor of Science in Accounting and Business Administration and is a Certified Public Accountant (inactive).
What is the salary of Justin File?
As the Chief Financial Officer of Evofem Biosciences Inc, the total compensation of Justin File at Evofem Biosciences Inc is $1,183,010. There are 5 executives at Evofem Biosciences Inc getting paid more, with Saundra Pelletier having the highest compensation of $2,803,980.
How old is Justin File?
Justin File is 49, he's been the Chief Financial Officer of Evofem Biosciences Inc since 2018. There are 12 older and 2 younger executives at Evofem Biosciences Inc. The oldest executive at Evofem Biosciences Inc is Gillian Greer, 75, who is the Independent Director.
What's Justin File's mailing address?
Justin's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130.
Insiders trading at Evofem Biosciences Inc
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link a Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.
What does Evofem Biosciences Inc do?
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
What does Evofem Biosciences Inc's logo look like?
Complete history of Mr. File stock trades at Evofem Biosciences Inc
Evofem Biosciences Inc executives and stock owners
Evofem Biosciences Inc executives and other stock owners filed with the SEC include:
-
Saundra Pelletier,
President, Chief Executive Officer, Director -
Kelly Culwell,
Chief Medical Officer -
Saundra Pelletier,
Pres, CEO & Director -
Thomas Lynch,
Chairman of the Board -
Russell Barrans,
Chief Commercial Officer -
Justin File,
Chief Financial Officer -
Justin J. File,
Chief Financial Officer -
Russell Barrans,
Chief Commercial Officer -
Tony O'Brien,
Independent Director -
William Hall,
Independent Director -
Colin Rutherford,
Independent Director -
Gillian Greer,
Independent Director -
Kim Kamdar,
Independent Director -
Amy Raskopf,
IR Contact Officer -
Lisa Rarick,
Independent Director -
Alexander Fitzpatrick,
Executive Vice President, General Counsel, Secretary -
Dr. Kelly Culwell M.D.,
Chief Medical Officer -
Kathy Gallo-Doyle,
VP of Sales -
Alexander A. Fitzpatrick Esq.,
Exec. VP, Gen. Counsel & Sec. -
Biopharma, Inc. Pdl,
10% owner -
Research Corp Acacia,
10% owner -
Anthony Stephen O'brien,
Director -
Yan Zhang,
CFO -
Ltd. Invesco,
10% owner -
Fund Solutions Ltd Link,
10% owner